Omnicell, Inc. reported a total revenue of $1.18 billion for the fiscal year ending December 31, 2025, marking a 7% increase from $1.11 billion in 2024. The growth was driven by a 6% rise in product revenues, which reached $665.7 million, and an 8% increase in service revenues, totaling $519.1 million. The company attributed the increase in service revenues to a growing installed customer base and pricing actions, particularly in its technical services and SaaS offerings. However, the company noted a decline in revenues from its XT Series automated dispensing systems, which are nearing the end of their lifecycle.
In terms of profitability, Omnicell's gross profit increased to $503.4 million, maintaining a gross margin of 42%. The cost of revenues rose by 6% to $681.4 million, primarily due to a significant increase in service-related costs, which were partially offset by a decrease in product costs attributed to favorable material costs and a reduction in restructuring expenses. Operating expenses also increased by 6% to $498.3 million, driven by higher employee-related costs and consulting expenses.
Omnicell's strategic developments included a focus on expanding its product offerings and enhancing its technology infrastructure to support the Autonomous Pharmacy vision. The company is investing in research and development to address challenges in medication management, particularly in light of workforce shortages and rising operational costs in the healthcare sector. The company also reported a full-time employee headcount of approximately 3,580 as of December 31, 2025, reflecting its commitment to scaling operations.
Looking ahead, Omnicell anticipates continued growth driven by the increasing demand for automation in medication management, particularly as healthcare providers face budget constraints and labor shortages. The company is also adapting to market conditions by shifting towards subscription-based revenue models, which may impact revenue recognition timing. However, potential risks include economic uncertainties, regulatory changes, and competition, which could affect future performance. The company remains focused on leveraging its technology and service offerings to enhance customer outcomes and drive long-term growth.
About OMNICELL, INC.
Omnicell designs and provides medication management automation, software workflows, and expert services for healthcare facilities. Its solutions enhance safety, efficiency, and patient adherence across inpatient, outpatient, and retail settings. Focused on the industry vision of the Autonomous Pharmacy, the company addresses challenges like labor shortages, medication errors, and rising drug costs, supporting healthcare providers worldwide with integrated, data-driven medication automation and optimization systems.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.